BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev 2021;35:940-62. [PMID: 34117095 DOI: 10.1101/gad.348523.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Donahue KL, Pasca di Magliano M. Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers. J Clin Invest 2022;132:e157168. [PMID: 35166242 DOI: 10.1172/JCI157168] [Reference Citation Analysis]
2 Mammarella E, Zampieri C, Panatta E, Melino G, Amelio I. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network. Biol Direct 2021;16:11. [PMID: 34348766 DOI: 10.1186/s13062-021-00296-5] [Reference Citation Analysis]
3 Wattenberg MM, Reiss KA. Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. Cancers (Basel) 2021;13:4716. [PMID: 34572943 DOI: 10.3390/cancers13184716] [Reference Citation Analysis]
4 Bots ST, Kemp V, Cramer SJ, van den Wollenberg DJ, Hornsveld M, Lamfers M, van der Pluijm G, Hoeben RC. Non-human primate adenoviruses of the Human Adenovirus B species are potent and broadly-acting oncolytic vector candidates. Hum Gene Ther 2021. [PMID: 34861769 DOI: 10.1089/hum.2021.216] [Reference Citation Analysis]
5 Silveira MAD, Bilodeau S, Greten TF, Wang XW, Trinchieri G. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer 2022:S2405-8033(22)00045-0. [PMID: 35331674 DOI: 10.1016/j.trecan.2022.02.009] [Reference Citation Analysis]
6 Maurici CE, Colenbier R, Wylleman B, Brancato L, van Zwol E, Van den Bossche J, Timmermans J, Giovannetti E, Mori da Cunha MGMC, Bogers J. Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. Biomolecules 2022;12:651. [DOI: 10.3390/biom12050651] [Reference Citation Analysis]
7 Lin Y, Schmidt MO, Sharif GM, Vietsch EE, Kiliti AJ, Barefoot ME, Riegel AT, Wellstein A. Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity. OncoImmunology 2022;11:2027136. [DOI: 10.1080/2162402x.2022.2027136] [Reference Citation Analysis]